<DOC>
	<DOCNO>NCT01707823</DOCNO>
	<brief_summary>This pilot clinical trial study low-dose acetylsalicylic acid treat patient stage I-III non-small cell lung cancer . Studying sample urine blood patient cancer laboratory may help doctor learn change biomarkers occur treatment acetylsalicylic acid</brief_summary>
	<brief_title>Low-Dose Acetylsalicylic Acid Treating Patients With Stage I-III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether ASA ( acetylsalicylic acid ) 325 mg inhibits prostaglandin E2 ( PGE2 ) biosynthesis patient early stage non-small cell lung cancer ( NSCLC ) . Cyclooxygenase ( COX ) catalytic activity determine measure metabolite PGE2 , 11alpha-hydroxy-9,12-dioxo-2,3,4,5-tetranor-prostane-1,20 dioic acid ( PGE-M ) urine pre- post-ASA 325 mg surrogate systemic PGE2 biosynthesis . SECONDARY OBJECTIVES : I . To determine whether COX-2 protein slow turnover adenocarcinoma lung . COX turnover determine measuring urinary PGE-M level daily 7 day discontinue ASA 325 mg. COX-2 Prostaglandin expression also measure tumor sample patient take time surgery . OUTLINE : Patients receive acetylsalicylic acid orally ( PO ) 7 day urine collect 7 day post therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>All patient early stage ( stage IIV ) nonsmall cell lung cancer , adenocarcinoma histology Patients see member Thoracic Surgical oncology Group Vanderbilt Ingram Cancer Center initial surgical consultation Patients take ASA nonsteroidal antiinflammatory drug ( NSAIDs ) last two week allergy ASA eligible enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>